Explore more price target data and ratings for Dyne Therapeutics, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Dyne Therapeutics, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. Thi…
Dyne Therapeutics entered into an Underwriting Agreement with Morgan Stanley & Jefferies, as representatives of the underwriters, for a public offering of 18,300,000 shares of common stock at $20.50 per share. Underwriters will purchase at $19.27 per share, and have a 30-day option to buy up to 2,7…
Dyne announced FDA acceptance of its BLA for z-rostudirsen with Priority Review and a Jan. 21, 2027 PDUFA date.Key Highlights:Original SEC Filing: Dyne Therapeutics, Inc. [ DYN ] - 8-K - Jul. 20, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important informatio…
- Priority Review granted; PDUFA target action date set for January 21, 2027 -- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint -- In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen once every 4 weeks resulted in a robust and st…
